ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Montréal, QC, CAN:

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: CC-96673

Phase 1

Celgene
Celgene

Montreal, Quebec, Canada and 12 other locations

immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non...

Enrolling
B-cell Non-Hodgkin Lymphoma
B-cell Lymphoma
Drug: IKS03

Phase 1

Iksuda Therapeutics

Montréal, Quebec, Canada and 2 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Montreal, Quebec, Canada and 37 other locations

with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma...

Active, not recruiting
B-cell Non-Hodgkin Lymphoma
Drug: Polatuzumab vedotin
Drug: Tocilizumab

Phase 1, Phase 2

Roche
Roche

Montreal, Quebec, Canada and 28 other locations

participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed folli...

Enrolling
Non-Hodgkin Lymphoma
Drug: Tocilizumab
Drug: Gemcitabine

Phase 3

Roche
Roche

Montreal, Quebec, Canada and 72 other locations

This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...

Active, not recruiting
Lymphoma, Non Hodgkin
Lymphocytic Leukemia, Chronic
Drug: BTCT4465A (Mosunetuzumab) IV
Drug: BTCT4465A (Mosunetuzumab) SC

Phase 1, Phase 2

Genentech
Genentech

Montréal, Quebec, Canada and 48 other locations

This is a phase I dose-escalation study of oral PCLX-001, conducted in a multicenter, non-randomized, open-label, non-controlled de...

Enrolling
B-cell Non Hodgkin Lymphoma
Advanced Solid Tumor
Drug: PCLX-001

Phase 1

Pacylex Pharmaceuticals

Montréal, Quebec, Canada and 3 other locations

evaluate the efficacy, safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non...

Active, not recruiting
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
Drug: Obinutuzumab
Drug: Zanubrutinib

Phase 2

BeiGene
BeiGene

Montréal, Quebec, Canada and 119 other locations

The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma...

Enrolling
Non-hodgkin Lymphoma
Drug: Epcoritamab

Phase 1

Genmab
Genmab

Montreal, Quebec, Canada and 40 other locations

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...

Enrolling
T-cell Lymphoma
Mantle Cell Lymphoma (MCL)
Drug: PRT2527
Drug: Zanubrutinib

Phase 1

Prelude Therapeutics

Montreal, Quebec, Canada and 23 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems